QUANTUM GENOMICS overview

Press Release Paris, March 13, 2024, 6 PM Quantum Genomics publishes its results for the 2023 financial year. The merger with ExactCure, which marks the strategic redeployment of the company and will be submiCed for a shareholder vote on April 24. Quantum Genomics (Euronext Growth—FR0011648971 - ALQGC) publishes its financial results for the 2023 financial year today. The Board of Directors approved the annual accounts, which met on March 12, 2024. The audit procedures have been carried out,...

ExactCure, a private French HealthTech company developing an innovative artificial intelligence device to tailor drug administration to each individual's profile A technology with CE marking, already implemented by significant healthcare solution providers and targeting pharmaceutical laboratories Completion of the merger expected in the first quarter of 2024 Extended financial visibility until the fourth quarter of 2024, with a consolidated cash position estimated at €3 million as of the...

Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC) , is pleased to announce its financial results for the first half of 2023 today. The semi-annual financial statements were approved by the Board of Directors during the meeting held on October 23, 2023. The limited review procedures of the semi-annual financial information by the Auditor are complete, and their report has been published. Audited financial statements (including complete financial statements and appendices) are available on...

After announcing on July 20, 2023, the signing of a letter of intent for a potential merger with Vistacare Medical, subject to satisfactory due diligence audits, Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC) today announces the termination of the exclusive negotiations with Vistacare Medical. Following the audits conducted by Quantum Genomics, the company believes that the financial prospects and the challenges related to Vistacare Medical's fragmented ownership structure do not...

Quantum Genomics enters into exclusive negotiations with Vistacare Medical with the ambition of creating a reference player in the management of complex wounds A French HealthTech company developing a revolutionary technology for treating complex wounds, with the support of the medical community A patented technology with CE marking already implemented in several French hospitals Complex wounds: a growing and voluminous market with unmet needs A business model offering strong recurring revenue...

Quantum Genomics releases its 2022 financial results and provides an update on its M&A discussions Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC) today announces its results for the full year 2022 and provides an update on its ongoing M&A discussions. The annual accounts were approved by the Board of Directors at the meeting held on May 25, 2023. The audit procedures have been conducted, and the audit report regarding the certification of the accounts is available on the Company's...

Quantum Genomics announces reorganization of its Board of Directors and staff restructuration in order to focus on new projects Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC), a biopharmaceutical company specialising in the development of a new class of medications that directly target the brain, announces a reorganization of its Board of Directors, a staff restructuration and renews the review of its strategy discussions. Reorganization of Quantum Genomics' Board of Directors On...

Quantum Genomics gives an update Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC), a biopharmaceutical company specialising in the development of a new class of medications that directly target the brain gives an update following the negative FRESH study results' announcement of last October 28, 2022. Cash position Cash position of the Company was M€ 10.6 as of December 7, 2022. The Company having taken the decision to stop REFRESH, its second phase III study in difficult to treat and...